Никлас, по ссылке фиброскана которую я дала , можно найти мыло адреса производителей и изобретателоей этого аппарата. там мыло на то и указано что бы к ним по всем вопросам обращаться. они все подробно объяснят
там даже прглашают на работу людей технологов которые будут обеспечивать обслуживание аппарата
устраивайся
)
смотри :
The company
EchoSens designs and markets medical imaging equipment developed from ultrasound elastography, the first application of which is measurement of hepatic fibrosis.
EchoSens is taking up a position in the new, promising market for non-invasive diagnosis of liver fibrosis, the consequence of chronic diseases such as hepatitis B and C and alcohol dependence.
EchoSens is actively seeking partners for distribution of its products.
EchoSens team
Maryse DARBOT | Marketing
Tel. : + 33 6 08 76 44 32
Stanislas DEMBINSKI | Business development
Tel. : + 33 6 85 84 96 25
Céline FOURNIER | Medical affairs
Bertrand FOURQUET | Managing Director - CFO
Jean-Michel GOMBERT | Area Sales Manager
Tel. : + 33 6 85 86 09 65
Jean-Michel HASQUENOPH | Technical Adviser
Véronique LAPORTE | Executive Assistant
Véronique MIETTE | Research & Development
Grégory PHILIPPE | Software Engineer
David POIZAT | Industrialization & Quality
Laurent SANDRIN | Technical Director
Sylvain YON | Technology & Development
Address
France
Headquarters
42, rue Monge - 75005 Paris
153, avenue d'Italie - 75013 Paris
Tel. : + 33 1 44 82 78 50
Fax : + 33 1 44 82 78 60
Distributor
Japon
Nippon EchoSens
C/O Nippon Eurotec
Atlantic Building 7th floor
3-3-2 , Azabudai Minato-ku, Tokyo
Tel.: +81 3 6229 2480 Fax : +81 3 3505 2071
Contact : M. Kuroiwa
kuroiwa@nippon-euro.co.jp
Partners
l'ANVAR Ile-de-France
www.anvar.fr
le BioCritt
www.biocritt.fr
le cabinet NODAL Consultants
www.nodal.fr
Association Française pour l'Etude du Foie
www.meditis.net/groupes/afef/accueil
SOS Hépatites
www.soshepatites.org
Hépatoweb
www.hepatoweb.com
а вот предложение о работе
EchoSens is looking for people with strong potential in order to pursue its development.
Please apply to:
recrutement@echosens.com
а теперь подробно, их публикация :
(ведь все есть на сайте лень те искать Никлас)
Abstract - Background & Aims: Transient elastography (FibroScanR) is a novel, non-invasive and rapid bedside method to assess liver fibrosis by measuring liver stiffness. We prospectively assessed the performance of FibroScanR in patients with chronic hepatitis C, in comparison to and combined with currently available biochemical markers (FibrotestR and APRI index); liver biopsy performed the same day served as the reference. Methods: We studied 183 consecutive patients with chronic hepatitis C (METAVIR fibrosis stage F1 n=47, F2 n=53, F3 n=37, F4 n=46). Results: FibroScanR values ranged from 2.4 to 75.4 kPa (median: 7.4 kPa). Cut-off values were 7.1 kPa for F>=2, 9.5 kPa for F>=3 and 12.5 kPa for F=4. The areas under the ROC curve of FibroScanR, FibroTest and APRI values were of the same order (0.83, 0.85 and 0.78, respectively, for F>=2; 0.90, 0.90 and 0.84, respectively, for F>=3; 0.95, 0.87 and 0.83, respectively, for F=4). The best performance was obtained by combining FibroScanR and FibroTestR, with areas under the ROC curve of 0.88 for F>=2, 0.95 for F>=3, and 0.95 for F=4. When the FibroScanR and FibroTestR results agreed, liver biopsy confirmed them in 84% of cases for F>=2, 95% for F>=3, and 94% for F=4. Conclusions: FibroScanR is a simple and effective method for assessing liver fibrosis, with similar performance to FibroTestR and APRI. Combined use of FibroScanR and FibroTestR to evaluate liver fibrosis could avoid biopsy in most patients with chronic hepatitis C.
M. Ziol, A. Handra-Luca, A. Kettaneh, C. Christidis, F. Mal, F. Kazemi, V. de LÈdinghen, P. Marcellin, D. Dhumeaux, J.C. Trinchet and M. Beaugrand.
Non-invasive assessment of liver fibrosis by stiffness measurement: a prospective multicentre study in patients with chronic hepatitis C.
Hepatology 2005;41(1):48-54.
Abstract -Because liver fibrosis is the main reliable predictor of the progression of chronic hepatitis C, its assessment by liver biopsy (LB) is proposed to help determine therapy. However, biopsy is an invasive procedure with several limitations. A new, non-invasive medical device based on transient elastography has been designed to measure liver stiffness. The aim of this study was to investigate the use of liver stiffness measurement (LSM) in the evaluation of liver fibrosis in patients with chronic hepatitis C. We prospectively enrolled 327 patients with chronic hepatitis C in a multicentre study. Patients underwent LB and LSM. METAVIR liver fibrosis stages were assessed on biopsy specimens by 2 pathologists. LSM were performed by transient elastography. Efficiency of LSM and optimal cut-off values for fibrosis stage assessment were determined by a receiver-operating characteristics (ROC) curve analysis and cross-validated by the jack-knife method. LSM was well correlated with fibrosis stage (Kendall correlation coefficient: 0.55, p < 0.0001). The area under ROC curves were 0.79 (95% confidence interval: 0.73-0.84) for F >= 2, 0.91 (0.87-0.96) for F >= 3, and 0.97 (0.93-1) for F = 4 and for larger biopsies, these values were respectively 0.81, 0.95 and 0.99. Optimal stiffness cut-off values of 8.7 and 14.5 kPa showed F >= 2 and F = 4, respectively. In conclusion, non-invasive assessment of liver stiffness with transient elastography appears reliable to detect significant fibrosis or cirrhosis in patients with chronic hepatitis C.
H. Saito, S. Tada, N. Nakamoto, K. Kitamura, H. Horikawa, S. Kurita, Y. Saito, H. Iwai and H. Ishii.
Efficacy of non-invasive elastometry on staging of hepatic fibrosis.
Hepatology Research 2004;29:97-103.
Abstract -To assess the efficacy of elastometry in the determination of fibrotic stage in the liver, we investigated correlation between liver histology and the elastometry using a device equipped with a vibrator and an echogram (Echosens, Paris, France) in patients with chronic hepatitis C. Totally 75 patients, 24 in F1 stage, 17 in F2 stage, 18 in F3 stage, and 16 in F4 stage according to the new Inuyama classification without fatty change were investigated. Correlations between the staging of liver fibrosis and elastometry, serum fibrosis makers and platelet counts were investigated. The elastometry was absolutely non-invasive. Serum fibrosis markers did not well correlate with the stage of liver fibrosis. Platelet counts significantly (p < 0.0001).
L. Sandrin, B. Fourquet, J.M. Hasquenoph, S. Yon, C. Fournier, F. Mal, C. Christidis, M. Ziol, B. Poulet, F. Kazemi, M. Beaugrand and R. Palau.
Transient elastography: a new non-invasive method for assessment of hepatic fibrosis.
Ultrasound in Medicine and Biology 2003;29(12):1705-1713.
Abstract -Chronic hepatitis is accompanied by progressive deposit of hepatic fibrosis, which may lead to cirrhosis. Evaluation of liver fibrosis is thus of great clinical interest and up to now is assessed with liver biopsy. This work aims to evaluate a new non-invasive device to quantify liver fibrosis: the shear elasticity probe or FibroScanR. This device is based on one-dimensional transient elastography, a technique that uses both ultrasound (5 MHz) and low-frequency (50 Hz) elastic waves, which propagation velocity is directly related to elasticity. The intra and inter-operator reproducibility of the technique as well as its ability to quantify liver fibrosis were evaluated in 106 patients with HCV chronic hepatitis. Liver elasticity measurements are reproducible (standardized coefficient of variation: 3%), operator-independent and well correlated (r = 0.81, p << 0.0001) to fibrosis grade (METAVIR). The areas under the ROC curves are 0.88 and 0.99 for the diagnosis of patients with significant fibrosis (>= F2) and with cirrhosis (= F4) respectively.
L. Sandrin, M. Tanter, J.L. Gennisson, S. Catheline and M. Fink.
Shear elasticity probe for soft tissues with 1-D transient elastography.
IEEE UFFC 2002;49:436-446.
Abstract -Important tissue parameters such as elasticity can be deduced from the study of the propagation of low frequency shear waves. A new method for measuring the shear velocity in soft tissues is presented in this paper. Unlike conventional transient elastography in which the ultrasonic transducer and the low frequency vibrator are two separated parts, the new method relies on a probe that associates the vibrator and the transducer, which is built on the axis of the vibrator. This setup is easy to use. The low frequency shear wave is driven by the transducer itself that acts as a piston while it is used in pulse echo mode to acquire ultrasonic lines. The results obtained with the new method are in good agreement with those obtained with the conventional one.
